二甲双胍通过激活腺苷酸活化蛋白激酶（AMPK）的抗肿瘤机制

Metformin, as a traditional oral hypoglycemic agent, is commonly used in the clinical treatment for type 2 diabetes. Recently, a large number of epidemiological researches have shown that metformin could reduce the tumor morbidity of type 2 diabetes, moreover, it has also been indicated that metformin could inhibit the growth, proliferation and transformation of cancer cells in metabolic pathways, cell cycle, oxidative stress and cancer/tumor stem cells transformation via AMPK pathway activation. But the antitumor e?ect of metformin via AMPK activation still exists arguments, and the defnite mechanism remains to be further investigated and confrmed by extensive clinical trials.